CurvaFix, Inc.
- Industry
- Medical Devices
- Founded Year
- 2013
- Headquarters
- Bellevue, Washington, United States
- Employee Count
- 28
Key People
- Mark Foster - CEO
- Steve Dimmer - Founder and Strategic Advisor
- Robert Meek - Inventor and Chair, Surgeon Advisory Board
- Bart Balkman - Chief Commercial Officer
- Carly Thaler - Director of R&D
- Nate Doran - Board Observer
- Michael Sjostrom - Board Member
- Marc Andre Marcotte - Board Member
- Trevor Moody - Board Member
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with significant industry experience.
The leadership team includes individuals with over a decade of experience in the medical device industry, enhancing the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's focus addresses a significant unmet need in orthopedic trauma.
CurvaFix's products target fragility fractures of the pelvis, a condition with limited effective treatments, indicating a strong clinical demand.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has several competitors, but CurvaFix offers unique solutions.
While companies like Acumed and Orthofix operate in the orthopedic device space, CurvaFix's focus on curved bone fractures provides a unique value proposition.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing implants for curved bones presents moderate technical challenges.
The design and manufacturing of implants that conform to curved bone structures require specialized engineering and materials, posing moderate challenges.
- Patent
-
Aspect: Strong
Summary: The company holds strong patents protecting its innovative products.
CurvaFix's proprietary technology is safeguarded by robust patents, enhancing its market position and deterring competitors.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding to support its operations.
With a $39 million Series C financing round led by MVM Partners, CurvaFix is well-positioned financially to advance its product development and commercialization efforts.
- Regulatory
-
Aspect: 510k/PMA
Summary: The company's flagship product has received FDA 510(k) clearance.
The CurvaFix IM Implant's FDA 510(k) clearance indicates compliance with regulatory standards, enabling its commercialization in the U.S. market.
Opportunity Rollup
- Odds of Success
- 4
- Peak Market Share
- 5.7
- Segment CAGR
- 3.0%
- Market Segment
- Orthopedic Devices
- Market Sub Segment
- Trauma Implants
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.29 |
| 2 | 0.86 |
| 3 | 2.00 |
| 4 | 3.99 |
| 5 | 5.70 |
Key Takeaway
CurvaFix's innovative approach to curved bone fracture repair, supported by strong leadership and substantial funding, positions it well in the orthopedic trauma market.